.RESEARCH HIGHLIGHT.16 October 2024.
In the NIAGARA hearing, the add-on of perioperative durvalumab to common therapy for muscle-invasive sac cancer cells improved event-free as well as generally survival, denoting a new procedure option for this ailment.